Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Scribe Therapeutics
Scribe Therapeutics is a biotech company that develops gene-editing therapies using CRISPR-CasX technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
PYC Therapeutics
PYC Therapeutics is a biotech firm based in Australia that is developing RNA-based drugs to treat genetic diseases.
Sector
Subsector
Keywords
total rounds
total raised
Abeona Therapeutics
Abeona Therapeutics is developing gene therapies and plasma-based products for life-threatening rare genetic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Shape Therapeutics
Shape Therapeutics is a biotech company that develops RNA technologies for gene therapy.
Sector
Subsector
Keywords
Location
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 30.11.2022. Their latest round Post-IPO Equity
Investments2
Kyverna Therapeutics
Kyverna Therapeutics is a company that is developing new therapies and cures for serious autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
SparingVision
SparingVision develops genomic medicines to treat blinding inherited retinal diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Investors9
Number of lead investors
Number of investors
Novartis
Novartis is a Swiss healthcare company improving global patient lives.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions1
Rewrite Therapeutics acquired by Intellia Therapeutics
acquirer
date
type
Rewrite Therapeutics
Rewrite Therapeutics is a private biotech company revolutionizing DNA writing technologies.
Sector
Subsector
Keywords
Location
People
Founders7
Rodolphe Barrangou
Rodolphe Barrangou is an Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina State University. His lab focuses on the biology and genetics of CRISPR/Cas immune systems in bacteria. He also serves on the Board of Directors of Caribou Biosciences. Rodolphe was previously a Director of Research and Development at DuPont and Danisco. While with Dansico, he was part of the team that initially established the adaptive immune function of CRISPR systems. Rodolphe received his PhD in Functional Genomics from North Carolina State University and an MBA from the University of Wisconsin, Madison.
current job
organization founded
Rodolphe Barrangou
Luciano Marraffini
Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano’s laboratory investigates the underlying molecular mechanisms of CRISPR immunity, and seeks to employ this natural pathway to develop new technologies. He is a 2012 Rita Allen Foundation Scholar and the recipient of a 2012 NIH Director’s New Innovator Award. Luciano received his PhD from the University of Chicago where he studied bacterial pathogenesis, and completed his postdoctoral fellowship at Northwestern University.
current job
organization founded
Luciano Marraffini
Nessan Bermingham
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
current job
organization founded
Nessan Bermingham
Employee Profiles79
Jeffrey Cehelsky
Vice president of development operations
Jennifer Kaufmann
Senior human resources operations manager
Ray Kelley
Vice president of financial planning analysis
Activity
Recent News17
The graph reveals the ratio (%) of positive news articles in a chosen time range